
Claims

1. The use of a compound of the genral formula (I)



(I),

in which

X represents O or NH , and

R^1 represents a methyl, ethyl, propyl or isopropyl group, and

R^2 and R^3 independently of one another represent hydrogen, a methyl or ethyl group, and

R^4 represents a C_1-C_6-alkyl group or a C_3-C_7-cycloalkyl ring,

and their physiologically acceptable salts, diastereomers and enantiomers

for treating tumors.

2. The use as claimed in claim 1 of a compound of the genral formula (I)

in which

X represents O or NH , and

R^1 represents a methyl group, and

R^2 represents a methyl group, and

R^3 represents hydrogen or a methyl group, and

R^4 represents a methyl or ethyl group or represents a cyclopropyl ring,

and their physiologically acceptable salts, diastereomers and enantiomers

for treating tumors.

3. The use of

- (*RS*)-*S*-cyclopropyl-*S*-(4-{[4-{[(1*R*,2*R*)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide
- (*RS*)-*S*-(4-{[4-{[(1*R*,2*R*)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-*S*-methylsulfoximide
- (*RS*)-*S*-(4-{[4-{[(*R*)-2-hydroxy-1,2-dimethylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-*S*-methylsulfoximide
- (*RS*)-*S*-cyclopropyl-*S*-(4-{[4-{[(1*R*,2*R*)-2-hydroxy-1-methylpropyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide
- (*RS*)-*S*-cyclopropyl-*S*-(4-{[4-{[(*R*)-2-hydroxy-1,2-dimethylpropyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide
- (*RS*)-*S*-ethyl-*S*-(4-{[4-{[(1*R*,2*R*)-2-hydroxy-1-methylpropyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide
- (*RS*)-*S*-ethyl-*S*-(4-{[4-{[(*R*)-2-hydroxy-1,2-dimethylpropyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide
- (*RS*)-*S*-(4-{[4-{[(1*R*,2*R*)-2-hydroxy-1-methylpropyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-*S*-methylsulfoximide
- (*RS*)-*S*-(4-{[4-{[(1*R*)-2-hydroxy-1,2-dimethylpropyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-*S*-methylsulfoximide

and their physiologically acceptable salts, diastereomers and enantiomers for treating tumors.


4. The use of a compound as claimed in any of claims 1 to 3 for preparing a medicament for treating tumors.

5. The use as claimed in any of claims 1 to 3 for treating breast carcinomas, pancreas carcinomas, kidney carcinomas, malignant melanomas and other skin tumors, small cell bronchial carcinomas, non-small cell bronchial carcinomas, colorectal carcinomas, ovarial carcinomas, cervix carcinomas, prostate carcinomas, leukemias or lymphomas.

~~6. The use as claimed in claim 5 for treating breast carcinomas, ovarial carcinomas, colorectal carcinomas, small-cell bronchial carcinomas or cervix carcinomas.~~

~~7~~1. The use of (*RS*)-*S*-(4-{[4-{[(1*R*,2*R*)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-*S*-methylsulfoximide and its physiologically acceptable salts, diastereomers and enantiomers for treating multidrug-resistant cervix carcinomas, colorectal carcinomas, small-cell bronchial carcinomas, breast carcinomas and cisplatin-resistant ovarial carcinomas.

~~8. A compound of the general formula (I)~~



(I),

~~in which~~

~~X represents O or NH, and~~

~~R^1 represents a methyl, ethyl, propyl or isopropyl group, and~~

~~R^2 and R^3 independently of one another represent hydrogen, a methyl or ethyl group, and~~

~~R^4 represents a C_1-C_6-alkyl group or a C_3-C_7-cycloalkyl ring,~~

~~and their physiologically acceptable salts, diastereomers and enantiomers for treating tumors.~~

~~9~~2. (*RS*)-*S*-(4-{[4-{[(1*R*,2*R*)-2-Hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)-*S*-methylsulfoximide and its physiologically acceptable salts, diastereomers and enantiomers for treating tumors.